Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities

被引:208
作者
Press, Joshua Z. [2 ]
De Luca, Alessandro [1 ]
Boyd, Niki [1 ]
Young, Sean [1 ,3 ]
Troussard, Armelle [1 ]
Ridge, Yolanda [3 ]
Kaurah, Pardeep [3 ]
Kalloger, Steve E. [4 ]
Blood, Katherine A. [1 ]
Smith, Margaret [5 ]
Spellman, Paul T. [6 ]
Wang, Yuker [7 ]
Miller, Dianne M. [8 ]
Horsman, Doug [1 ,5 ]
Faham, Malek [7 ]
Gilks, C. Blake [1 ,4 ]
Gray, Joe [6 ]
Huntsman, David G. [1 ,3 ,4 ]
机构
[1] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada
[2] Univ British Columbia, Dept Obstet & Gynecol, Vancouver, BC V5Z 1M9, Canada
[3] Univ British Columbia, Hereditary Canc Program, Vancouver, BC V5Z 1M9, Canada
[4] Vancouver Gen Hosp, Genet Pathol Evaluat Ctr Prostate Ctr, Vancouver, BC, Canada
[5] Royal Melbourne Hosp, Parkville, Vic 3050, Australia
[6] Univ Calif San Francisco, Lawrence Berkeley Natl Lab, Div Life Sci, San Francisco, CA 94143 USA
[7] Affymetrix Inc, San Francisco, CA USA
[8] Univ British Columbia, Dept Gynecol Oncol, Vancouver, BC V5Z 1M9, Canada
关键词
D O I
10.1186/1471-2407-8-17
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Subclassification of ovarian carcinomas can be used to guide treatment and determine prognosis. Germline and somatic mutations, loss of heterozygosity (LOH), and epigenetic events such as promoter hypermethylation can lead to decreased expression of BRCA1/2 in ovarian cancers. The mechanism of BRCA1/2 loss is a potential method of subclassifying high grade serous carcinomas. Methods: A consecutive series of 49 ovarian cancers was assessed for mutations status of BRCA1 and BRCA2, LOH at the BRCA1 and BRCA2 loci, methylation of the BRCA1 promoter, BRCA1, BRCA2, PTEN, and PIK3CA transcript levels, PIK3CA gene copy number, and BRCA1, p21, p53, and WT-1 immunohistochemistry. Results: Eighteen (37%) of the ovarian carcinomas had germline or somatic BRCA1 mutations, or epigenetic loss of BRCA1. All of these tumours were high-grade serous or undifferentiated type. None of the endometrioid (n = 5), clear cell (n = 4), or low grade serous (n = 2) carcinomas showed loss of BRCA1, whereas 47% of the 38 high-grade serous or undifferentiated carcinomas had loss of BRCA1. It was possible to distinguish high grade serous carcinomas with BRCA1 mutations from those with epigenetic BRCA1 loss: tumours with BRCA1 mutations typically had decreased PTEN mRNA levels while those with epigenetic loss of BRCA1 had copy number gain of PIK3CA. Overexpression of p53 with loss of p21 expression occurred significantly more frequently in high grade serous carcinomas with epigenetic loss of BRCA1, compared to high grade serous tumors without loss of BRCA1. Conclusion: High grade serous carcinomas can be subclassified into three groups: BRCA1 loss (genetic), BRCA1 loss (epigenetic), and no BRCA1 loss. Tumors in these groups show distinct molecular alterations involving the PI3K/AKT and p53 pathways.
引用
收藏
页数:12
相关论文
共 82 条
[1]   Expression profiling and individualisation of treatment for ovarian cancer [J].
Agarwal, Roshan ;
Kaye, Stan B. .
CURRENT OPINION IN PHARMACOLOGY, 2006, 6 (04) :345-349
[2]   WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma [J].
Al-Hussaini, M ;
Stockman, A ;
Foster, H ;
McCluggage, WG .
HISTOPATHOLOGY, 2004, 44 (02) :109-115
[3]   A PHYSICAL MAP AND CANDIDATE GENES IN THE BRCA1 REGION ON CHROMOSOME 17Q12-21 [J].
ALBERTSEN, HM ;
SMITH, SA ;
MAZOYER, S ;
FUJIMOTO, E ;
STEVENS, J ;
WILLIAMS, B ;
RODRIGUEZ, P ;
CROPP, CS ;
SLIJEPCEVIC, P ;
CARLSON, M ;
ROBERTSON, M ;
BRADLEY, P ;
LAWRENCE, E ;
HARRINGTON, T ;
SHENG, ZM ;
HOOPES, R ;
STERNBERG, N ;
BROTHMAN, A ;
CALLAHAN, R ;
PONDER, BAJ ;
WHITE, R .
NATURE GENETICS, 1994, 7 (04) :472-479
[4]  
[Anonymous], 2004, STAT APPL GENET MOL, DOI DOI 10.2202/1544-6115.1095
[5]   The pathology of inherited breast cancer [J].
Armes, JE ;
Venter, DJ .
PATHOLOGY, 2002, 34 (04) :309-314
[6]  
Aunoble B, 2000, INT J ONCOL, V16, P567
[7]   Origins and molecular pathology of ovarian cancer [J].
Bell, DA .
MODERN PATHOLOGY, 2005, 18 :S19-S32
[8]   MOLECULAR ALTERATIONS OF THE AKT2 ONCOGENE IN OVARIAN AND BREAST CARCINOMAS [J].
BELLACOSA, A ;
DEFEO, D ;
GODWIN, AK ;
BELL, DW ;
CHENG, JQ ;
ALTOMARE, DA ;
WAN, MH ;
DUBEAU, L ;
SCAMBIA, G ;
MASCIULLO, V ;
FERRANDINA, G ;
PANICI, PB ;
MANCUSO, S ;
NERI, G ;
TESTA, JR .
INTERNATIONAL JOURNAL OF CANCER, 1995, 64 (04) :280-285
[9]   Cellular functions of the BRCA tumour-suppressor proteins [J].
Boulton, S. J. .
BIOCHEMICAL SOCIETY TRANSACTIONS, 2006, 34 :633-645
[10]   Clinicopathologic features of BRCA-linked and sporadic ovarian cancer [J].
Boyd, J ;
Sonoda, Y ;
Federici, MG ;
Bogomolniy, F ;
Rhei, E ;
Maresco, DL ;
Saigo, PE ;
Almadrones, LA ;
Barakat, RR ;
Brown, CL ;
Chi, DS ;
Curtin, JP ;
Poynor, EA ;
Hoskins, WJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (17) :2260-2265